PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

o a collection of information unless it displays a valid OMB control number.					
1	Application Number	10/510,314			
Filing Date First Named Inventor		October 1, 2004			
		Sean Lilienfeld et al.			
Group Art Unit		1616			
I	Examiner Name				
ı	Attorney Docket Number	JAB1705USPCT			
ı	1				

Examiner's Cite Initials' Cite No.! Include name of the author (in CAPITAL LETTERS), title of the atticle (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published FULTON, Bret et al. "Galanthamine", Drugs and Aging, 1996, pp. 60-65	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner's Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item				
			(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²			
FULTON, Bret et al. "Galanthamine", Drugs and Aging, 1996, pp. 60-65	Initials*	No.1	publisher, city and/or country where published				
			FULTON, Bret et al. "Galanthamine", Drugs and Aging, 1996, pp. 60-65				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.